Experimental Psychology, Thach Hall, Auburn University, AL 36849, USA.
Pharmacol Biochem Behav. 2011 Jan;97(3):551-9. doi: 10.1016/j.pbb.2010.10.011. Epub 2010 Nov 2.
Variability is a functional and modifiable component of behavior that is necessary for learning or behavior change to occur. An appreciation of drug effects on reinforced variability could contribute to a fuller understanding of potential drug effects on behavior change. Dopamine agonists were examined under conditions that produced low and high levels of variability. In Experiment 1, D-amphetamine and dopamine-receptor-specific agonists (quinpirole and SKF 38393) were examined with rats that lever-pressed under a Multiple VARY 8:4 Fixed Ratio 4 (FR 4) schedule. In the VARY 8:4 condition, reinforcement followed every four-response sequence that differed from the previous eight sequences. Any four-response sequence was reinforced in the FR 4 component. Experiment 2 was an attempt to hold overall reinforcement rate constant by reinforcing criterion sequences under a Variable Interval 60" schedule of reinforcement. In Experiment 1, D-amphetamine and quinpirole (D₂ agonist) increased variability in the FR 4 component while having no effect on variability in the VARY 8:4 component. SKF 38393 (D₁ agonist) had little effect on variability, even at doses that lowered total responding. In Experiment 2, intermittent reinforcement elevated variability in the FR 4 component and attenuated differential effects of D-amphetamine. Thus, D-amphetamine and quinpirole increased variability when it was low under the FR 4 component in Experiment 1. The high variability under the VARY 8:4 schedule was unaffected by D-amphetamine, except for modest effects at high doses. These observations suggest that dopamine and specifically D₂-type receptors are involved in the production of behavioral variability, and that the drug effects depend upon the baseline level of variability.
变异性是行为的一种功能和可修饰的组成部分,对于学习或行为改变的发生是必要的。对药物对强化变异性的影响的认识,可以有助于更全面地理解潜在的药物对行为改变的影响。在产生低水平和高水平变异性的条件下,研究了多巴胺激动剂。在实验 1 中,用在多重 VARY 8:4 固定比率 4(FR 4)方案下按压杠杆的大鼠检查了 D-苯丙胺和多巴胺受体特异性激动剂(喹吡罗和 SKF 38393)。在 VARY 8:4 条件下,每四个与前八个序列不同的反应序列都会得到强化。在 FR 4 成分中,任何四个反应序列都会得到强化。实验 2 试图通过在可变间隔 60"强化方案下强化标准序列来保持整体强化率常数。在实验 1 中,D-苯丙胺和喹吡罗(D₂激动剂)增加了 FR 4 成分的变异性,而对 VARY 8:4 成分的变异性没有影响。SKF 38393(D₁激动剂)几乎没有影响变异性,即使在降低总反应的剂量下也是如此。在实验 2 中,间歇性强化提高了 FR 4 成分的变异性,并减弱了 D-苯丙胺的差异作用。因此,在实验 1 中,当 FR 4 成分中的变异性较低时,D-苯丙胺和喹吡罗增加了变异性。在 VARY 8:4 方案下的高变异性不受 D-苯丙胺的影响,除了在高剂量时会产生适度的影响。这些观察结果表明,多巴胺特别是 D₂型受体参与了行为变异性的产生,并且药物作用取决于基线变异性水平。